The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | Herman Jenny | CAO | Sell(S) | 608 | $12.84 | $8K |
| Mar 5, 2026 | Akinsanya Karen | See Remarks | Sell(S) | 1K | $12.90 | $18K |
| Mar 5, 2026 | Farid Ramy | President & CEO, Director | Sell(S) | 4K | $12.91 | $47K |
| Mar 5, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | Sell(S) | 1K | $12.90 | $16K |
| Mar 5, 2026 | Tran Yvonne | EVP, CLO & CPO | Sell(S) | 1K | $12.90 | $14K |
| Mar 5, 2026 | Herman Jenny | CAO | Sell(S) | 775 | $12.85 | $10K |
| Mar 5, 2026 | Jain Rachit | EVP & CFO | Sell(S) | 2K | $12.90 | $21K |
| Mar 4, 2026 | Abel Robert Lorne | See Remarks | Sell(S) | 1K | $12.81 | $17K |
| Mar 2, 2026 | Akinsanya Karen | See Remarks | Grant(A) | 24K | — | $0 |
| Mar 2, 2026 | Akinsanya Karen | See Remarks | Sell(S) | 2K | $11.99 | $26K |
| Mar 2, 2026 | Akinsanya Karen | See Remarks | Grant(A) | 28K | — | $0 |
| Mar 2, 2026 | Akinsanya Karen | See Remarks | Grant(A) | 6K | — | $0 |
| Mar 2, 2026 | Akinsanya Karen | See Remarks | Grant(A) | 49K | — | $0 |
| Mar 2, 2026 | Farid Ramy | President & CEO, Director | Grant(A) | 56K | — | $0 |
| Mar 2, 2026 | Farid Ramy | President & CEO, Director | Sell(S) | 6K | $11.90 | $66K |
| Mar 2, 2026 | Farid Ramy | President & CEO, Director | Grant(A) | 48K | — | $0 |
| Mar 2, 2026 | Farid Ramy | President & CEO, Director | Grant(A) | 14K | — | $0 |
| Mar 2, 2026 | Farid Ramy | President & CEO, Director | Grant(A) | 113K | — | $0 |
| Mar 2, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | Grant(A) | 21K | — | $0 |
| Mar 2, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | Grant(A) | 17K | — | $0 |
| Mar 2, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | Grant(A) | 34K | — | $0 |
| Mar 2, 2026 | Tran Yvonne | EVP, CLO & CPO | Grant(A) | 17K | — | $0 |
| Mar 2, 2026 | Tran Yvonne | EVP, CLO & CPO | Grant(A) | 14K | — | $0 |
| Mar 2, 2026 | Tran Yvonne | EVP, CLO & CPO | Grant(A) | 34K | — | $0 |
| Mar 2, 2026 | Herman Jenny | CAO | Grant(A) | 10K | — | $0 |
| Mar 2, 2026 | Herman Jenny | CAO | Grant(A) | 8K | — | $0 |
| Mar 2, 2026 | Abel Robert Lorne | See Remarks | Grant(A) | 17K | — | $0 |
| Mar 2, 2026 | Abel Robert Lorne | See Remarks | Grant(A) | 21K | — | $0 |
| Mar 2, 2026 | Abel Robert Lorne | See Remarks | Grant(A) | 34K | — | $0 |
| Mar 2, 2026 | Friesner Richard | Director | Option exercise(M) | 161K | $3.07 | $493K |
| Mar 2, 2026 | Friesner Richard | Director | Option exercise(M) | 161K | — | $0 |
| Mar 2, 2026 | Aklian Mannix Vartan | See Remarks | Grant(A) | 17K | — | $0 |
| Mar 2, 2026 | Aklian Mannix Vartan | See Remarks | Grant(A) | 34K | — | $0 |
| Mar 2, 2026 | Jain Rachit | EVP & CFO | Grant(A) | 17K | — | $0 |
| Mar 2, 2026 | Jain Rachit | EVP & CFO | Grant(A) | 34K | — | $0 |
| Feb 10, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | Sell(S) | 925 | $13.73 | $13K |
| Feb 10, 2026 | Tran Yvonne | EVP, CLO & CPO | Sell(S) | 776 | $13.80 | $11K |
| Feb 10, 2026 | Herman Jenny | CAO | Sell(S) | 752 | $13.79 | $10K |
| Feb 9, 2026 | Abel Robert Lorne | See Remarks | Sell(S) | 1K | $13.51 | $17K |
| Oct 16, 2025 | Dugan Margaret | Chief Medical Officer | Sell(S) | 1K | $21.07 | $29K |
| Jun 18, 2025 | Friesner Richard | Director | Grant(A) | 6K | — | $0 |
| Jun 18, 2025 | Friesner Richard | Director | Grant(A) | 9K | — | $0 |
| Jun 18, 2025 | Oberoi Arun | Director | Grant(A) | 6K | — | $0 |
| Jun 18, 2025 | Oberoi Arun | Director | Grant(A) | 9K | — | $0 |
| Jun 18, 2025 | Ginsberg Gary L | Director | Grant(A) | 6K | — | $0 |
| Jun 18, 2025 | Ginsberg Gary L | Director | Grant(A) | 9K | — | $0 |
| Jun 18, 2025 | Kapeller-Libermann Rosana | Director | Grant(A) | 6K | — | $0 |
| Jun 18, 2025 | Kapeller-Libermann Rosana | Director | Grant(A) | 9K | — | $0 |
| Jun 18, 2025 | Thornberry Nancy | Director | Grant(A) | 6K | — | $0 |
| Jun 18, 2025 | Thornberry Nancy | Director | Grant(A) | 9K | — | $0 |
| Jun 18, 2025 | van Kralingen Bridget A | Director | Grant(A) | 1K | — | $0 |
| Jun 18, 2025 | van Kralingen Bridget A | Director | Grant(A) | 2K | — | $0 |
| Jun 18, 2025 | Lynton Michael | Director | Grant(A) | 6K | — | $0 |
| Jun 18, 2025 | Lynton Michael | Director | Grant(A) | 9K | — | $0 |
| Jun 18, 2025 | Sender Gary | Director | Grant(A) | 6K | — | $0 |
| Jun 18, 2025 | Sender Gary | Director | Grant(A) | 9K | — | $0 |
| Jun 18, 2025 | Chodakewitz Jeffrey | Director | Grant(A) | 6K | — | $0 |
| Jun 18, 2025 | Chodakewitz Jeffrey | Director | Grant(A) | 9K | — | $0 |
| May 29, 2025 | Aklian Mannix Vartan | See Remarks | Grant(A) | 14K | — | $0 |
| May 29, 2025 | Aklian Mannix Vartan | See Remarks | Grant(A) | 84K | — | $0 |
| May 21, 2025 | Jain Rachit | EVP & CFO | Grant(A) | 9K | — | $0 |
| May 21, 2025 | Jain Rachit | EVP & CFO | Grant(A) | 19K | — | $0 |
| Apr 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Sell(S) | 8K | $25.11 | $210K |
| Apr 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Option exercise(M) | 13K | $3.22 | $43K |
| Apr 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Option exercise(M) | 3K | $2.92 | $10K |
| Apr 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Sell(S) | 5K | $25.11 | $126K |
| Apr 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Sell(S) | 3K | $25.00 | $84K |
| Apr 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Option exercise(M) | 13K | — | $0 |
| Apr 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Option exercise(M) | 3K | — | $0 |
| Mar 7, 2025 | van Kralingen Bridget A | Director | Grant(A) | 10K | — | $0 |
| Mar 7, 2025 | van Kralingen Bridget A | Director | Grant(A) | 17K | — | $0 |
| Mar 6, 2025 | Herman Jenny | SVP & Controller | Sell(S) | 666 | $21.11 | $14K |
| Mar 3, 2025 | Abel Robert Lorne | See Remarks | Grant(A) | 13K | — | $0 |
| Mar 3, 2025 | Abel Robert Lorne | See Remarks | Grant(A) | 50K | — | $0 |
| Mar 3, 2025 | Tran Yvonne | EVP, CLO & CPO | Grant(A) | 13K | — | $0 |
| Mar 3, 2025 | Tran Yvonne | EVP, CLO & CPO | Grant(A) | 50K | — | $0 |
| Mar 3, 2025 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | Grant(A) | 13K | — | $0 |
| Mar 3, 2025 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | Grant(A) | 50K | — | $0 |
| Mar 3, 2025 | Herman Jenny | SVP & Controller | Grant(A) | 10K | — | $0 |
| Mar 3, 2025 | Herman Jenny | SVP & Controller | Grant(A) | 8K | — | $0 |
| Mar 3, 2025 | Dugan Margaret | Chief Medical Officer | Grant(A) | 13K | — | $0 |
| Mar 3, 2025 | Dugan Margaret | Chief Medical Officer | Grant(A) | 50K | — | $0 |
| Mar 3, 2025 | Farid Ramy | President & CEO, Director | Grant(A) | 38K | — | $0 |
| Mar 3, 2025 | Farid Ramy | President & CEO, Director | Grant(A) | 60K | — | $0 |
| Mar 3, 2025 | Farid Ramy | President & CEO, Director | Grant(A) | 90K | — | $0 |
| Mar 3, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Grant(A) | 16K | — | $0 |
| Mar 3, 2025 | Akinsanya Karen | President of R&D, Therapeutics | Grant(A) | 63K | — | $0 |
| Mar 3, 2025 | Porges Geoffrey Craig | EVP & CFO | Grant(A) | 15K | — | $0 |
| Mar 3, 2025 | Porges Geoffrey Craig | EVP & CFO | Sell(S) | 5K | $21.76 | $119K |
| Mar 3, 2025 | Porges Geoffrey Craig | EVP & CFO | Grant(A) | 13K | — | $0 |
| Mar 3, 2025 | Porges Geoffrey Craig | EVP & CFO | Grant(A) | 50K | — | $0 |
| Feb 18, 2025 | Tran Yvonne | EVP, CLO & CPO | Option exercise(M) | 4K | $4.34 | $17K |
| Feb 18, 2025 | Tran Yvonne | EVP, CLO & CPO | Sell(S) | 4K | $28.00 | $109K |
| Feb 18, 2025 | Tran Yvonne | EVP, CLO & CPO | Option exercise(M) | 4K | — | $0 |
| Feb 11, 2025 | Tran Yvonne | EVP, CLO & CPO | Sell(S) | 828 | $24.43 | $20K |
| Feb 11, 2025 | Herman Jenny | SVP & Controller | Sell(S) | 859 | $24.43 | $21K |
| Feb 11, 2025 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | Sell(S) | 985 | $24.43 | $24K |
| Feb 10, 2025 | Abel Robert Lorne | See Remarks | Sell(S) | 1K | $25.99 | $32K |
| Oct 15, 2024 | Dugan Margaret | Chief Medical Officer | Sell(S) | 2K | $17.78 | $27K |
| Jun 18, 2024 | Ginsberg Gary L | Director | Grant(A) | 5K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).